SCHEMBL17184268

SCHEMBL17184268

Cc1ccccc1Nc1c(C(=O)N2CCC(c3ccc(F)cc3)CC2)cnc(S(=O)(=O)c2ccccc2)c1Cl

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDE4A P27815 2/20 0.41
▸ PDE4B Q07343 2/20 0.41
▸ PDE4C Q08493 2/20 0.41
▸ PDE4D Q08499 2/20 0.41
▸ MAPT P10636 2/20 0.40
▸ FASN P49327 6/20 0.40
▸ PRSS12 P56730 1/20 0.39
▸ HSD11B1 P28845 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ MGLL Q99685 1/20 0.37
▸ CCR1 P32246 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ SIRT5 Q9NXA8 1/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ ATM Q13315 1/20 0.36
▸ POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17134928 0.91 FASN (0.41) MAPTFASNPRSS12HSD11B1ALDH1A1
SCHEMBL17184249 0.91 FASN (0.41) MAPTFASNPRSS12HSD11B1ALDH1A1
SCHEMBL17134927 0.90 FASN (0.41) MAPTFASNPRSS12HSD11B1ALDH1A1
SCHEMBL17134767 0.87 MAPT (0.43) MAPTFASNPRSS12HSD11B1ALDH1A1
SCHEMBL17134520 0.85 MAPT (0.41) MAPTFASNPRSS12HSD11B1ALDH1A1
SCHEMBL17134725 0.84 FASN (0.42) MAPTFASNHSD11B1ALDH1A1CCR1
SCHEMBL17135227 0.84 FASN (0.37) MAPTFASNPRSS12HSD11B1ALDH1A1
SCHEMBL17134537 0.84 PRSS12 (0.41) MAPTFASNPRSS12ALDH1A1MGLL
SCHEMBL17134614 0.84 FASN (0.42) MAPTFASNHSD11B1ALDH1A1CCR1
SCHEMBL17134984 0.83 MAPT (0.43) MAPTFASNPRSS12HSD11B1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9701689-B2 Substituted pyridines and pyridazines as CCR10 receptor inhibitors KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-07-11 — — US disclosed
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2015-10-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND ARG1, H1-0, TYR PDE4A 2958/4885PDE4B 3655/4885PDE4C 2922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback